Third Age Health Services Limited Consolidated Statement of Comprehensive Income For the year ended 31 March 2024

2024	Restated*
	ćooo
\$000	\$000
Revenue 15,151	11,217
Cost of services (6,735)	(5,174)
Gross profit 8,416	6,043
Other income 85	35
Employees and contractors (3,652)	(2,814)
Professional and consulting fees (437)	(503)
Other expenses (1,419)	(970)
Operational expenses (5,508)	(4,287)
Loan impairment -	(233)
EBITDA 2,993	1,558
Depreciation (413)	(319)
Amortisation of intangibles (316)	(240)
Finance costs (360)	(292)
Profit before income tax 1,904	707
Income tax expense (543)	(316)
Profit for the period 1,361	391
Other comprehensive income -	-
Total comprehensive income for the period 1,361	391
Profit and total comprehensive income attributable to:	
Shareholders of the parent 1,381	418
Non-controlling interests (20)	(27)
Profit for the year 1,361	391
Earnings per share	
Basic earnings per share (cents) 13.81	4.18
Diluted earnings per share (cents) 13.81	4.18

^{*} Refer note 10

Third Age Health Services Limited Consolidated statement of changes in equity For the year ended 31 March 2024

		Share			
		Based		Non-	
	Share	Payments	Retained	controlling	
	Capital	Reserve	earnings	Interest	Total
	\$000	\$000	\$000	\$000	\$000
Balance at 1 April 2022	515	643	1,538	-	2,696
Profit for the year (restated)		-	418	(27)	391
Total comprehensive income for the year (restated)	-	-	418	(27)	391
Shares issued	81	-	-	-	81
Dividend	-	-	(647)	-	(647)
Tax credit on share based payments	-	4	-	-	4
Deferred tax credit on share based payments	-	(10)	-	-	(10)
Share based payments	-	8	-	-	8
Balance at 31 March 2023 (restated)	596	645	1,309	(27)	2,523
Balance at 1 April 2023	596	645	1,309	(27)	2,523
Retained earnings adjustment (note 11)	-	-	(61)	-	(61)
Revised balance at 1 April 2023	596	645	1,248	(27)	2,462
Profit for the year	-	-	1,381	(20)	1,361
Total comprehensive income for the year	-	-	1,381	(20)	1,361
Shares issued	-	-	-	-	-
Dividend	-	-	(984)	-	(984)
Tax credit on share based payments	-	-	-	-	-
Deferred tax credit on share based payments	-	-	-	-	-
Share based payments		12	-		12
Balance at 31 March 2024	596	657	1,645	(47)	2,851

^{*} Refer note 10

Third Age Health Services Limited Consolidated Statement of Financial Position For the year ended 31 March 2024

		Restated*
	2024	2023
	\$000	\$000
Current assets	·	
Cash and cash equivalents	1,695	1,355
Trade and other receivables	1,173	1,326
Loan receivable	, -	80
Total current assets	2,868	2,761
Non-current assets		
Property, plant and equipment	224	255
Right-of-use-assets	2,500	2,967
Intangible assets	4,191	4,370
Trade and other receivables	20	20
Total non-current assets	6,935	7,612
Total assets	9,803	10,373
	5,803	10,373
Current liabilities		
Trade and other payables	1,931	1,582
Current tax liabilities	344	94
Bank Loan	1,342	281
Lease liabilities	306	283
Total current liabilities	3,923	2,240
Non current liabilities		
Other payables	1	2
Lease liabilities	2,399	2,755
Provisions	167	163
Deferred tax liability	462	630
Bank Loan	-	2,060
Total non current liabilities	3,029	5,610
Total liabilities	6,952	7,850
Net assets	2,851	2,523
Equity	2,031	2,323
Share capital	596	596
Share based payment reserve	657	645
Retained earnings	1,598	1,282
Equity attributable to the Group	2,851	2,523
Shareholders of the parent	2,860	2,528
Non-Controlling Interests	(9)	(5)
Total Equity	2,851	2,523
		,

^{*} Refer note 10

Third Age Health Services Limited Consolidated Statement of Cash Flows For the year ended 31 March 2024

	2024	2023
	\$000	\$000
Cash flows from operating activities		
Receipts from customers	15,351	10,402
Payments to suppliers and employees	(11,891)	(8,989)
Interest received	38	7
Interest paid	(372)	(244)
Income taxes paid	(450)	(390)
Net cash flows from operating activities	2,676	786
Cash flows from investing activities		
Payments purchase for property, plant and equipment	(18)	(52)
Payments for investment in software development	(132)	-
Acquisition of general practices	-	(2,004)
Net cash flows used in investing activities	(150)	(2,056)
Cash flows from financing activities		
Share purchase plan deposits applied to acquire shares	-	(76)
Proceeds from issuing shares	-	72
Loan repayments	(919)	(37)
Payment of lease liabilities	(283)	(198)
Dividend paid	(984)	(638)
Proceeds from bank loan	-	2,378
Net cash flows from financing activities	(2,186)	1,501
Net increase in cash and cash equivalents	340	231
Cash and cash equivalents at the beginning of the period	1,355	1,124
Cash and cash equivalents at the end of the period	1,695	1,355

1. Reporting entity

These Consolidated Financial Statements are for Third Age Health Services Limited and its subsidiaries (the "Group"). The Parent is incorporated and domiciled in New Zealand and registered under the Companies Act 1993. The parent's shares are publicly traded on the New Zealand Stock Exchange (NZX) and are listed on the main board of the NZX. The principal trading activity of the Group is the provision of medical services to the aged care sector.

2. Statement of accounting policies

Accounting policies remain consistent with the prior year ended 31 March 2023 financial statements.

3. Net tangible assets

The Group has net tangible assets as at 31 March 2024 of (8.8) cents per share (2023: net tangible assets (11.7) cents per share). The movement in net tangible assets is the results of changes in the Statement of Financial Position composition owing to the repayment of borrowings in the year.

4. Segment information

4.1. Products and services from which reportable segments derive their revenue

The Group's reportable segments are as follows:

- Aged medical residential care services, being the provision of medical care services to the aged care sector.
- · General practice medical services

4.2. Segment revenues and results

The following is an analysis of the Group's revenue and results from operations by reportable segment:

		Restated*
Segment revenue	2024	2023
	\$000	\$000
Aged medical care services	8,283	5,948
General practice medical services	6,868	5,269
Total for continuing operations	15,151	11,217
Segment profit before tax	2024	2023
	\$000	\$000
Aged medical care services	1,830	709
General practice medical services	74	(2)
Total for continuing operations	1,904	707

^{*} Refer note 10

Segment profit includes the following items:

Segment profit includes the following items:

For the year ended 31 March 2023 (restated refer note 10)

EBITDA 713 845 Depreciation (4) (315) Amortisation of intangibles - (240) Interest expense on leases 99 (150) Interest on ANZ Loan - (43) Interest on Loss on modification of borrowings - (43) Profit before tax 709 (2) Add back: Loan impairment 233 - Profit before tax from underlying core operations 92 (2) Income tax expense (268) (48) Profit for the period 441 (50) For the year ended 31 March 2024 Aged care medical services medical services medical services medical services s	Aged Care	General practice
EBITDA \$000 \$000 Depreciation (4) (315) Amortisation of intangibles - (240) Interest expense on leases - (99) Interest on ANZ Loan - (150) Interest on Loss on modification of borrowings - (43) Profit before tax 709 (2) Add back: Loan impairment 233 - Profit before tax from underlying core operations 942 (2) Income tax expense (268) (48) Profit for the period 441 (50) For the year ended 31 March 2024 Aged care medical services medical services medical services feed services on the period services		deficial practice
EBITDA 713 845 Depreciation (4) (315) Amortisation of intangibles - (240) Interest expense on leases - (99) Interest on ANZ Loan - (150) Interest on Loss on modification of borrowings - (43) Profit before tax 709 (2) Add back: Loan impairment 233 - Profit before tax from underlying core operations 942 (2) Income tax expense (268) (48) Profit for the period 441 (50) For the year ended 31 March 2024 Aged care medical services medical services medical services some	medical services	medical services
Depreciation (4) (315) Amortisation of intangibles - (240) Interest expense on leases - (99) Interest on ANZ Loan - (150) Interest on Loss on modification of borrowings - (43) Profit before tax 709 (2) Add back: Loan impairment 233 - Profit before tax from underlying core operations 942 (2) Income tax expense (268) (48) Profit for the period 441 (50) For the year ended 31 March 2024 Aged care medical services medical services medical services medical services foot medical services in medical services foot services in medical services in med	\$000	\$000
Amortisation of intangibles - (240) Interest expense on leases - (99) Interest on ANZ Loan - (150) Interest on Loss on modification of borrowings - (43) Profit before tax 709 (2) Add back: Loan impairment 233 - Profit before tax from underlying core operations 942 (2) Income tax expense (268) (48) Profit for the period 441 (50) For the year ended 31 March 2024 Aged care medical services medical services For the year ended 31 March 2024 1,809 1,148 Depreciation (6) (407) Amortisation of intangibles - (316) Interest expense on leases - (209) Interest on ANZ Loan - (151)	713	845
Interest expense on leases	(4)	(315)
Interest on ANZ Loan	-	(240)
Interest on Loss on modification of borrowings Profit before tax Add back: Loan impairment Profit before tax from underlying core operations Profit before tax from underlying core operations Profit for the period Profit for the period Profit for the period Profit before tax from underlying core operations Profit for the period Profit before tax from underlying core operations Profit before tax from underlying	-	(99)
Profit before tax 709 (2) Add back: Loan impairment 233 - Profit before tax from underlying core operations 942 (2) Income tax expense (268) (48) Profit for the period 441 (50) For the year ended 31 March 2024 Aged care medical services medical services medical services medical services sources 5000 \$000 EBITDA 1,809 1,148 Depreciation (6) (407) Amortisation of intangibles - (316) Interest expense on leases - (209) Interest on ANZ Loan - (151)	-	(150)
Add back: Loan impairment 233 - Profit before tax from underlying core operations 942 (2) Income tax expense (268) (48) Profit for the period 441 (50) For the year ended 31 March 2024 Aged care medical services medical services medical services medical services medical services medical services EBITDA 1,809 1,148 Depreciation (6) (407) Amortisation of intangibles - (316) Interest expense on leases - (209) Interest on ANZ Loan - (151)	-	(43)
Profit before tax from underlying core operations942(2)Income tax expense(268)(48)Profit for the period441(50)For the year ended 31 March 2024Aged care medical services medical services medical services some medical services followsmedical services medical services medical services followsEBITDA1,8091,148Depreciation(6)(407)Amortisation of intangibles-(316)Interest expense on leases-(209)Interest on ANZ Loan-(151)	709	(2)
Note 100	233	-
Profit for the period 441 (50) For the year ended 31 March 2024 Aged care medical services medical services medical services medical services medical services medical services medical services medical services EBITDA 1,809 1,148 Depreciation (6) (407) Amortisation of intangibles - (316) Interest expense on leases - (209) Interest on ANZ Loan - (151)	942	(2)
Profit for the period 441 (50) For the year ended 31 March 2024 Aged care medical services medical services medical services medical services medical services medical services medical services medical services EBITDA 1,809 1,148 Depreciation (6) (407) Amortisation of intangibles - (316) Interest expense on leases - (209) Interest on ANZ Loan - (151)	(268)	(48)
For the year ended 31 March 2024 Aged care medical services medical services some some some some some some some so	` ,	
Medical services medical services medical services \$000 \$000 EBITDA 1,809 1,148 Depreciation (6) (407) Amortisation of intangibles - (316) Interest expense on leases - (209) Interest on ANZ Loan - (151)	1	
EBITDA \$000 \$000 Depreciation 1,809 1,148 Amortisation of intangibles 6 (407) Interest expense on leases - (209) Interest on ANZ Loan - (151)	Aged care	General practice
EBITDA 1,809 1,148 Depreciation (6) (407) Amortisation of intangibles - (316) Interest expense on leases - (209) Interest on ANZ Loan - (151)	medical services	medical services
Depreciation (6) (407) Amortisation of intangibles - (316) Interest expense on leases - (209) Interest on ANZ Loan - (151)	\$000	\$000
Amortisation of intangibles - (316) Interest expense on leases - (209) Interest on ANZ Loan - (151)	1,809	1,148
Interest expense on leases - (209) Interest on ANZ Loan - (151)	(6)	(407)
Interest on ANZ Loan - (151)	-	(316)
· ·	-	(209)
Interest income	-	(151)
Interest income 27 9	27	9
Profit before tax 1,830 74	1,830	74
Add back: Loan impairment	-	_
Profit before tax from underlying core operations 1,830 74	1,830	74
Income tax expense (496) (47)	(496)	(47)
Profit for the period 1,334 27	1,334	27
Add back: Loan impairment Profit before tax from underlying core operations Income tax expense		713 (4) 709 233 942 (268) 441 Aged care medical services \$000 1,809 (6) 27 1,830 - 1,830 (496)

EBITDA represents profit before tax excluding amounts for depreciation and amortisation expenses, interest expenses and interest income.

4.3. Segment assets and liabilities

		Restated*
Segment assets	2024	2023
	\$000	\$000
Aged medical care services including support functions	2,638	2,444
General practice medical services	8,366	9,114
Total segment assets	11,004	11,558
Intercompany elimination	(1,201)	(1,185)
Total segment assets	9,803	10,373
		D t - t - 1*
Command Habilitation		Restated*
Segment liabilities	2024	2023
	\$000	\$000
Aged medical care services including support functions	1,461	1,012
General practice medical services	6,692	8,023
Total segment liabilities	8,153	9,035
Intercompany elimination	(1,201)	(1,185)
Total segment liabilities	6,952	7,850

5. Costs of employees, contractors, and directors includes:

	2024	2023
	\$000	\$000
Salaries and wages	2,919	2,334
Short term incentives	197	40
Defined contribution (KiwiSaver)	179	132
Share based payments expense	13	8
Employee benefit expense	3,308	2,514
Contractors	344	300
	3,652	2,814

Costs of employees has increased due to the full year impact of salaries and wages for the three new practices.

6. Finance Costs

		Restated*
	2024 \$000	2023 \$000
Interest expense on leases	209	150
Interest on ANZ Loan	151	99
Interest on Loss on modification of borrowings	<u> </u>	43
	360	292
* 5 () 40		

^{*} Refer note 10

7. Share Capital

Ordinary shares

All ordinary shares rank equally with one vote attached to each fully paid share. Total issued share capital is 10,004,149 ordinary shares (2023: 10,004,149). At 1 April 2021 there were 250,000 shares held for specific participants of the historic Third Age Employee Share Purchase Plan Trust ("**Trust"**). During the year ended 31 March 2022, 200,000 shares were issued and the remaining 50,000 shares were issued during the year ended 31 March 2023. As at 31 March 2024, of the total number of issued shares, nil (2023: nil) were held in trust for specific participants under the Employee Share Purchase Plan.

		Treasury shares		Authorised
	Issued	and shares held	Total	issued and fully
	Share Capital	in Trust		paid shares
	\$000	\$000	\$000	000's
Balance at 1 April 2023	596	-	596	10,004
Shares issued	-	-	-	-
Share issue transaction costs		-	-	
Balance at 31 March 2024	596		596	10,004
Balance at 1 April 2022	592	(76)	516	10,000
Shares issued	8	76	84	4
Share issue transaction costs	(4)		(4)	
Balance at 31 March 2023	596		596	10,004

8. Earnings per share

Basic earnings per share is calculated by dividing the profit attributable to the shareholders of the parent by the weighted average number of ordinary shares outstanding during the financial year, excluding treasury shares.

Diluted earnings per share adjusts the figures used in the determination of basic earnings per share to take into account the after-income tax effect of interest and other financing costs associated with dilutive potential ordinary shares, and the weighted average number of ordinary shares that would have been outstanding assuming the conversion of all dilutive potential ordinary shares.

Reconciliation of earnings used in calculating earnings per share

		Restated*
	2024 \$000	2023 \$000
Net profit attributable to the ordinary shareholders of the parent	1,381	418
Earnings used in the calculation of basic earnings per share	1,381	418

Weighted average number of shares used as the denominator	or	
	2024	2023
	Shares	Shares
	000's	000's
Weighted average number of ordinary shares used as the denominator in calculating basic earnings per share	10,004	10,004
Adjustments for calculation of diluted earnings per share: Employee share options	-	-
Weighted average number of ordinary shares and potential ordinary shares used as the denominator in calculating diluted earnings per share	40.004	40.004
-	10,004	10,004

Share options issued under Employee share options plan are considered as antidilutive.

9. Dividends

Dividends declared and paid during the year ended 31 March 2024:	Cents per share	\$000
Interim dividend Q3	3.31	313
Interim dividend Q2	2.34	221
Interim dividend Q1	1.62	154
Final dividend for the year ended 31 March 2023	5.03	403
	12.30	1,091
Dividends declared and paid during the year ended 31 March 2023:	Cents per share	\$000
Interim dividend	2.45	244
Final dividend for the year ended 31 March 2022	4.05	403
	6.50	647

10. Restatement on additional provision for 'make good' and reclassifications

Upon a further review of IFRS16 para 24(d), the company has made an additional provision allowing for tenant obligations under its leases for making good on the premises at the end of each lease that it holds. The provisions are preliminary and have been made on a conservative basis approach. The provision and subsequent profit impacts, amortising the restated 'make good' asset since the inception of the leases has impacted the current year, as well as the prior year as follows:

Extract from Consolidated Statement of Comprehensive Income	Previously reported 2023 \$000	IFRS 16 \$000	Restated 2023 \$000
EBITDA	1,558	-	1,558
Depreciation	(304)	(15)	(319)
Amortisation of intangibles	(240)	-	(240)
Finance costs	(286)	(6)	(292)
Profit before income tax	728	(21)	707
Income tax expense	(316)	-	(316)
Profit for the period	412	(21)	391

As per the table below, reclassifications have been made as at 31 March 2023 in the Consolidated Statement of Financial Position. These reclassifications have had no impact on net assets or equity as at 31 March 2023.

				Restated
Restated Consolidated Statement of Financial Position	2023	IFRS 16	Reclassification	2023
	\$000	\$000	\$000	\$000
Current assets				
Cash and cash equivalents	1,355	-	-	1,355
Trade and other receivables	1,117	-	209	1,326
Loan receivable	80	-	-	80
Total current assets	2,552	-	209	2,761
Non-current assets				
Property, plant and equipment	154	120	(19)	255
Right-of-use-assets	2,967	-	-	2,967
Intangible assets	4,351	-	19	4,370
Trade and other receivables	20	-	-	20
Total non-current assets	7,492	120	-	7,612
Total assets	10,044	120	209	10,373
Current liabilities				
Trade and other payables	1,395	-	187	1,582
Current tax liabilities	94	-	-	94
Bank Loan - current	281	-	-	281
Lease liabilities	283	-	-	283
Total current liabilities	2,053	-	187	2,240
Non current liabilities				
Trade and other payables	2	-	-	2
Lease liabilities	2,755	-	_	2,755
Provisions	-	141	22	163
Deferred tax liability	630	-	_	630
Bank Loan	2,060	-	_	2,060

Total non current liabilities Total liabilities	2023 \$000 5,447 7,500	\$000 141 141	Reclassification \$000 22 209	Restated 2023 \$000 5,610 7,850
Net assets	2,544	(21)		2,523
Equity				:
Share capital	596	-	_	596
Share based payment reserve	645	-	-	645
Retained earnings	1,303	(21)	-	1,282
Equity attributable to the Group	2,544	(21)	-	2,523
Shareholders of the parent	2,549	(21)	-	2,528
Non-Controlling Interests	(5)	-	-	(5)
Total Equity	2,544	(21)		2,523

11. IFRS 16 lease recalculations

Upon review of IFRS16 and recalculation of our lease obligations, adjustments have been made to current year retained earnings shown in our Consolidated Statement of Changes in Equity. These changes are not material, and have been included in the year ending 31 March 2024 (retained earnings reduced by \$61k).